Oral administration of MDL 19,301 (N-(l,3-dithiolan-2-ylidene)-4-hexyl-benzenamine) inhibited rat paw edema induced by carrageenan (ED30 4.8 mg/kg) or an Arthus reaction (ED30 8.2 mgikg p.0.). The oral dose which induced gastric ulceration in 50% of fasted rats (UD50) was greater than 1,000 mgikg, demonstrating a more favorable therapeutic ratio than conventional nonsteroidal anti-inflammatory agents. Its major metabolite (MDLI 6,861, 4[( 1,3-dithiolan-2-yliden)arnino]-benzeneacetic acid) was also a potent inhibitor of carrageenan paw edema (ED50 5.5 mgikg P.o.), although it was more ulcerogenic (UD50 52 mgikg p.0.). The anti-inflammatory activity of MDL 19,301, but not that of MDL 16,861, was attenuated by co-administration of an inhibitor of drug metabolism (SK&F525A 30 mgikg i.p.). This suggests that MDL 19,301 is a prodrug of MDL 16,861 and this phenomenon would explain its lack of ulcerogenicity. Additional anti-inflammatory properties of MDL 19,301 included inhibition of carrageenan pleurisy, adjuvant arthritis, and acetic-acid-induced writhing. Other pharmacological data indicate that MDL 19,301 administration results in inhibition of prostaglandin synthesis; inhibition of arachidonic-acidinduced, but not prostaglandin-E2-induced, diarrhea in mice; and inhibition of ex vivo arachidonic-acid-induced, but not adenosine-diphosphate-induced, rat platelet aggregation. MDL 19,301 and MDL 16,861 were unexpectedly weak antipyretic agents in rats. In summary, MDL 19,301 is an anti-inflammatory, analgesic prodrug which, unlike conventional agents, is devoid of ulcerogenic activity at therapeutic doses.